Rifat Pamukcu

Cell Pathways, Inc. develops and commercializes drugs for the prevention and treatment of cancer

Midway Pharmaceuticals, Inc. develops non-antibiotic therapies. It capitalizes on the finding the molecular weight polymers, taken orally but not systemically absorbed, can inhibit the pathogenic behavior of bacteria in the GI tract, enhance gut barrier function and promote gastrointestinal healing. The company was founded by John Alverdy, Eugene Chang and Elaine Petrof in 2005 and is headquartered in Spring House, PA.

Atrin Pharmaceuticals LLC engages in discovery and development of proprietary medications. It offers ATRN-502, a p53 activator; and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. The firm also provides Atrize, a platform that offers phenotypic FACS-based screening that is applicable across R&D, clinical applications, and a tool for personalized medicine. The company was founded by Oren Gilad and Kevin D. Smith in 2011 and is headquartered in Doylestown, PA.

RxMP Therapeutics, Inc. develops and designs novel hemostatic agents to arrest or prevent excessive bleeding. The company is headquartered in Miami, FL.

Virion Therapeutics LLC develops chronic viral disease vaccines. It offers ChiVax and ChiVax-gD vaccines. The firm engages in developing immune-based treatments for virally-associated cancers and chronic viral infections. The company was founded by Bernard C. Rudnick, Hildegund C. J. Ertl and Andrew D. Luber in 2018 and is headquartered in Newark, DE.

Syantra, Inc. engages in the development of cancer detection and treatment technology. It offers Syantra DX - Breast Cancer, a blood-based cancer detection assay that utilizes a novel suite of biomarkers and proprietary artificial intelligence-generated algorithms to provide a positive or negative result. The company was founded by Kristina Rinker and Kenneth Fuh and is headquartered in Calgary, Canada.

SIRPant Immunotherapeutics, Inc. is a clinical-stage immuno-oncology company based in Hummelstown, PA. The company specializes in developing next-generation macrophage-based immunotherapies for the treatment of hematological malignancies and solid tumors. The cell therapy technology employed by SIRPant is based on the reduction of SIRP? expression combined with activation of the patient's own macrophages. This population of SIRP?low activated macrophages is designed to attack the tumor following injection by activating the patient's immune system to produce broad-spectrum anti-tumor activity that utilizes patient T-cells and antibodies targeting cancer neoantigens. The company was founded by Richard F. Fitzgerald, and the CEO is Robert J. Towarnicki.

Founded in 2012, Atrin Pharmaceuticals, Inc. is a DNA Damage Response development company that focuses on a pipeline of products resulting from a series of novel conformationally restricted macrocyclic molecules. Part of Aprea Therapeutics, Inc., the company is based in Doylestown, PA. Atrin Pharmaceuticals was acquired by Aprea Therapeutics, Inc. on May 16, 2022 for $1.33 million. The company's products have the highest known potency for inhibiting ATR and exhibit ATR selectivity with potential broad therapeutic profile.